Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody …
WebDec 10, 2022 · Talquetamab, a new, off-the-shelf bispecific antibody against the novel target GPRC5D, had substantial antitumor effects in patients with heavily pretreated relapsed or refractory multiple...
U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class ...
WebHORSHAM, Pa., Aug. 10, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of TALVEY™ (talquetamab-tgvs), a first-in-class bispecific antibody for the treatment of adult patients with relapsed or refractory multiple myeloma who ...
Talquetamab - Wikipedia
WebMedical uses. Talquetamab is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, …
WebDec 10, 2022 · Talquetamab, a bispecific antibody against CD3 and GPRC5D, redirects T cells to mediate killing of GPRC5D-expressing myeloma cells. METHODS.
Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a …
WebMay 31, 2023 · Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM). | Journal of Clinical Oncology. Free access. Hematologic Malignancies—Plasma Cell Dyscrasia. May 31, 2023.
WebTalquetamab is a bispecific antibody that redirects T cells to mediate killing of myeloma cells expressing the recep- tor GPRC5D, which has not been previously targeted.
A novel T cell-redirecting anti-GPRC5D × CD3 bispecific ... - Nature
WebMar 1, 2024 · Here, we constructed BsAb5003, a novel humanized bispecific monoclonal antibody targeting CD3 and GPRC5D, and evaluated its therapeutic impact on MM. BsAb5003 induced specific cytotoxicity of...
FDA approves first GPRC5D × CD3-targeted bispecific for ... - Nature
WebNEWS IN BRIEF. 06 September 2023. FDA approves first GPRC5D × CD3-targeted bispecific for multiple myeloma. By. Asher Mullard. The FDA has granted accelerated approval to Johnson &...
Talquetamab: First Approval - PubMed
WebTalquetamab (talquetamab-tgvs; TALVEY ® ), a humanized, bispecific G-protein coupled receptor family C group 5 member D (GPRC5D)-directed CD3 T-cell engager, is being developed by Janssen for the treatment of multiple myeloma (MM). In early August 2023, talquetamab was granted accelerated a …
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody …
WebDec 15, 2022 · Talquetamab, a bispecific antibody against CD3 and GPRC5D, redirects T cells to mediate killing of GPRC5D-expressing myeloma cells.
Skip to content